About the International Psoriasis Council
Founded in 2004, the International Psoriasis Council (IPC) is a dermatologist-led, voluntary, global, nonprofit organization with a network of psoriasis experts, thought leaders, and professionals, dedicated to improving patient care around the globe.

Global Psoriasis Leadership
With more than 100 board members and councilors from 32 countries, IPC embodies the global expertise of multispecialty psoriasis key opinion leaders. These leaders include representatives from dermatology, basic science, translational research, genetics, epidemiology, cardiology, psychology, international clinical trials, and direct patient care.

Vision
A world free of psoriasis.

Mission
To improve the care of people with psoriasis worldwide, through education, research, and advocacy.

STRATEGIC AIMS

EXPAND IPC’S PRESENCE AND INFLUENCE with individual health care practitioners around the globe

INCREASE ACTIVITIES in underserved countries and increase our network of key opinion leaders

ELEVATE THE STANDARD OF CARE for those living with psoriasis, with a focus on individual outcomes

FACILITATE THE EXCHANGE OF SCIENTIFIC IDEAS and encourage collaboration between researchers around the globe

SUPPORT AND ENCOURAGE the next generation of psoriasis leaders

ENHANCE THE UNDERSTANDING OF PSORIASIS as a serious, systemic disease with multiple associated comorbidities
Dear Colleagues,

It’s been more than six months since I began my tenure as International Psoriasis Council (IPC) President and I am honoured to lead the organization as we continue to improve the care of people with psoriasis worldwide through education, research, and advocacy. As I reflect on all that we accomplished in 2018, I want to first begin by thanking you – our dedicated board of directors, councillors, and corporate partners – for the time, energy and resources you devoted to helping further our important work.

2018 was a very successful year for IPC during which we increased our global activities and impact on education. Highlights include:

• The successful launch of the IPC International Fellowship Program with early-career dermatologist/researchers interested in psoriasis who were provided full access to the knowledge of our network of experts, representing our commitment to encouraging and supporting the next generation of psoriasis leaders;

• Educational symposia participation that included more than 1,100 attendees from around the globe;

• Webcasts and online Continuing Medical Education (CME) programs that educated more than 1,500 health care practitioners worldwide;

• Inaugural IPC master classes held in Spain and India, with more than 125 participants, which are designed to improve the standard of care for people living with psoriasis in those regions; and

• The psoriasis disease severity classification project, which enjoyed widespread participation; manuscripts are currently in development.

In the year ahead you will see the IPC board and staff engaging more fully with our councillors and corporate partners from around the world, and I invite you to utilize our website to keep up to date on our activities and events.

On behalf of the IPC board of directors, thank you for invaluable support and we look forward to partnering with you. Together we will continue to advance our work and mission.

Prof. Jonathan Barker, MD, FRCP, FRCPath
President
International Psoriasis Council
### Officers
- Jonathan Barker, President, United Kingdom
- Craig L. Leonardi, Vice President/President-Elect, United States
- Bruce Strober, Secretary/Treasurer, United States
- Christy Langan, Chief Executive Officer, United States

As of December 2018

### Directors
- Hervé Bachelez, France
- Claudia de la Cruz, Chile
- Christopher EM Griffiths, United Kingdom
- Robert Holland III, United States
- Lars Iversen, Denmark
- Alexa B. Kimball, Immediate Past President, United States
- Alan Menter, Founding President, United States
- Lluís Puig, Spain
- Ricardo Romiti, Brazil

### COUNCILORS

#### Africa
- South Africa
  - Gail Todd
- Asia
  - China
    - Xuejun Zhang
    - Min Zheng
  - India
    - Muridhar Rajagopalan
- Malaysia
  - Siew Eng Choon
- Philippines
  - Veren Verallo-Rowell
- Singapore
  - Wei-Sheng Chong
  - Colin Theng
- Europe
  - Austria
    - Georg Stingl
    - Robert Strohal
  - Belgium
    - Jo Lambert
  - Denmark
    - Lone Skov
    - Claus Zachariae
  - France
    - Denis Jullien
    - Carle Paul
    - Manuelle Viguier
  - Germany
    - Matthias Augustin
    - Ulrich Mrowietz
    - Alexander Nast
    - Jörg Prinz
    - Christian Reich
    - Robert Sabat
    - Wolfram Sterry
    - Diamant Thaçi
  - Ireland
    - Brian Kirby
    - Caitriona Ryan
  - Italy
    - Giampiero Girolomoni
    - Paolo Gisondi
  - Portugal
    - Tiago Torres
  - Spain
    - Carlos Ferrándiz
  - United Kingdom
    - Darren Ashcroft
    - Ian Bruce
    - Christine Bundy
    - Arthur David Burden
    - Robert Chalmers

#### North America
- Canada
  - Robert Bissonnette
  - Marc Bourcier
  - Wayne Gulliver
  - Charles W. Lynde
  - Richard Langley
  - Yves Poulin
  - Ronald Vender
- United States
  - April Armstrong
  - Andrew Blauvelt
  - Anne Bowcock
  - Kristina Callis Duffin
  - Clay Cockerell
  - Kevin Cooper
  - Kelly M. Cordon
  - JT Elder
  - Charles Ellis
  - Colby Evans
  - Joel Gelfand
  - Kenneth Gordon
  - Alice Gottlieb
  - Johann Gudjonsson
  - Robert E. Kalb
  - Francisco Kerdel
  - Gerald Krueger
  - James Krueger
  - Mark Lebwohl
  - Nehal Mehta
  - Amy Paller
  - David Pariser
  - Mark Pittelkow
  - Linda Stein Gold
  - Nicole L. Ward
  - Jashin Wu
- Oceania
  - Australia
    - Peter Foley

#### Latin America
- Argentina
  - Edgardo Chouela
  - Cristina Echeverria
  - Matias Maskin
- Brazil
  - Gladys Aires-Martins
  - André Vicente
  - Esteves de Carvalho
- Chile
  - Fernando Valenzuela
- Colombia
  - César Gonzalez
  - Angela Londoño
- Mexico
  - Nancy Podoswa
- Middle East
  - Egypt
    - Mahira Hamdy El Sayed
    - Mohamed EL-Komy
  - Iran
    - Omid Zargari
  - Israel
    - Arnon D. Cohen
- Kuwait
  - Nawaf Al-Mutairi

**Long-time IPC councilor elected to IPC Board of Directors**

Professor Lluís Puig is director of the Dermatology Department at the Hospital de la Santa Creu i Sant Pau (HSCSP) in Barcelona, Spain, and professor of dermatology at Autonomous University of Barcelona (UAB) Medical School. Over the past 10 years, Professor Puig has focused his clinical research on the treatment of psoriasis with biological agents and has participated in 21 clinical trials to date. The results of his research have been presented at both national and international meetings and have been the subject of more than 250 papers, including review articles and continuous medical education papers, and 10 international book chapters. He is a member of the European Academy of Dermatology and Venereology (EADV), American Academy of Dermatology (AAD), European Society for Dermatological Research (ESDR), The American Society of Dermatopathology (ASDP), International Society of Dermatopathology (ISDP), and Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA). He has been a councilor of the IPC since 2012.
IPC COMMITTEES

BOARD COMMITTEES

Executive Committee
Chair
Jonathan Barker
President, United Kingdom

Members
Craig Leonardi
Vice President & President-Elect, United States
Bruce Strober
Treasurer/Secretary, United States
Alexa Kimball
Immediate Past President, United States
Claudia de la Cruz
Education Chair, Chile
Hervé Bachelez
Research Chair, France
Christy Langan
CEO, United States

Finance Committee
Chair
Bruce Strober
United States

Members
Jonathan Barker
United Kingdom
Robert Holland III
United States
Christy Langan
United States

Education and Outreach Committee
Chair
Claudia de la Cruz
Chile

Members
Edgardo Chouela
Argentina
Mahira El Sayed
Egypt
Paolo Gisondi
Italy
Elise Kleyn
United Kingdom
Mark Lebwohl
United States
Mark Pittelkow
United States
Murlidhar Rajagopalan
India
Colin Theng
Singapore

Staff Liaisons
Christy Langan
Nicora Gardner
Peter van de Kerkhof

Patient Care Committee
Chair
Bruce Strober
United States

Members
Andrew Blauvelt
United States
Wolf-Henning Boehncke
Switzerland
Arnon Cohen
Israel
Chris Griffiths
United Kingdom
Alice Gottlieb
United States
Caitriona Ryan
Ireland
Lone Skov
Denmark
Fernando Valenzuela
Chile
Jashin Wu
United States

Staff Liaisons
Joelle van der Walt
Peter van de Kerkhof

Research Committee
Chair
Hervé Bachelez
France

Members
April Armstrong
United States
André Carvalho
Brazil
Michel Gilliet
Switzerland
Johann Gudjonsson
United States
Lars Iversen
Denmark
Nehal Mehta
United States
Jörg Prinz
Germany
Ricardo Romiti
Brazil

Staff Liaisons
Joelle van der Walt
Peter van de Kerkhof

2018 Outstanding Volunteers
IPC councilors volunteer their time and expertise in support of the organization. In 2018, nearly 90% of our councilors participated in IPC projects and programs. We were pleased to recognize these five councilors at our Annual IPC Think Tank meeting as our 2018 Outstanding Volunteers:

Arnon Cohen
Israel
Elise Kleyn
United Kingdom
Murlidhar Rajagopalan
India
Fernando Valenzuela
Chile
Xuejun Zhang
China
In 2018 IPC’s work and influence were felt worldwide. From educational symposia and exhibitions at important congress, to making connections with future leaders in psoriasis through Master Classes and our Fellowship program, IPC’s presence was vast and far-reaching.

6 new councilors in 2018 from 5 countries

Francesca Capon
London, United Kingdom

Mohamed EL-Komy
Cairo, Egypt

Denis Jullien
Lyon, France

Jo Lambert
Ghent, Belgium

Masamoto Murkami
Matsuyama, Japan

Tadashi Terui
Tokyo, Japan
GLOBAL OUTREACH

IPC International Fellows Program launch a resounding success

Aiming to increase the number of scientists and clinicians who focus on treating and researching psoriasis, the IPC launched the International Fellowship Program in 2018 to provide training and real-world practice for early-career dermatologists or junior faculty who have completed their training within the last 5 years. In 2018, the program awarded 3 fellowships to recipients who were matched with IPC board members and councilors in their laboratories and clinics to observe and participate in research and patient care.

- Daniela Armijo, MD, from Chile, studied with IPC Past President Professor Chris Griffiths at the University of Manchester in the United Kingdom;
- Jiaqi Chen, PhD, from China, studied with Dr. Curdin Conrad, MD, at the University Hospital of Lausanne in Switzerland; and
- Filip Rob, MD, from the Czech Republic, studied with Dr. Joel Gelfand, MD, MSCE, at the University of Pennsylvania.

Program sponsors: AbbVie, Amgen, Janssen Biotech, LEO Pharma and Novartis

IPC’s 2018 Fellows shown here during the European Academy of Dermatology and Venereology Congress in Paris, France. In addition to the on-site observation with their chosen mentors, IPC’s awarded fellows attend one major international dermatology congress and the annual IPC Think Tank as part of their year long fellowship.

Latin America Working Group convenes in Mexico and Brazil

The care of patients living with psoriasis in Latin America represents many unique challenges due to lack of knowledge of the burden of psoriasis in this region and limited access to care. This IPC working group assembles regional experts to highlight these issues on an international stage, bringing influence and awareness to dermatologists throughout the region.

The working group organized symposia at two important regional congresses, including the annual meeting of Latin American Dermatologists (RADLA) in Cancun, Mexico, and the Congreso Iberoamericano de Dermatología (CILAD) in São Paulo, Brazil. Additionally, the working group meetings held during these congresses brought consensus among the members to focus their efforts in the coming year, including a paper on tuberculosis and an analysis of the dermatology residency programs in the region.

Chairs: Claudia de la Cruz, MD, and Ricardo Romiti, MD, PhD

Celebrating a successful IPC symposium at RADLA in Cancun, Mexico, are, left to right, IPC CEO Christy Langan, IPC Councilor Matías Maskin, IPC Board Members Ricardo Romiti and Claudia de la Cruz, IPC Councilor André Carvalho, presenter Tatjana Maul, and IPC Councilor Fernando Valenzuela.
Educational symposia participation tops 1,100

More than 1,100 health care professionals participated in IPC symposia during 2018 at various congresses around the world. Programs were held in Brazil, China, France, Mexico, India, Spain, and the United States. Speakers covered a variety of topics, including patient-centered psoriasis management and empowering doctors and their patients to make well-educated decisions as a team. They also made multiple presentations on challenging cases as well as new and emerging therapies.

IPC Psoriasis Master Class launches in Spain and India

The IPC launched its Psoriasis Master Class Program in 2018, with successful programs held in Barcelona, Spain, and Mumbai, India. More than 125 attendees participated in these one-and-a-half-day intensive programs, which provided a comprehensive approach to psoriasis management and equipped attendees with the latest and most cutting-edge information available. The programs were led by both international and regional psoriasis experts in an effort to customize the program to the regions' unique needs.

Continuing Medical Education (CME) Initiative

Webcasts and online programs educate more than 1,500 health care practitioners

- Virtual patient case study challenges: Managing psoriasis and its comorbidities
  - Pregnancy
  - Hodgkin disease
- Webcast: Individualizing Treatment in Psoriasis: Empowering You and Your Patients to Make Well-Educated Decisions as a Team
- Webcast: Advances in Psoriasis: A Focus on New and Emerging Therapies
- Webcast: Clinical Challenges in Psoriasis: Advancing the Standard of Care

Program sponsors: Janssen Scientific Affairs, LLC; Eli Lilly; and Sun Pharma

Serving as faculty for IPC’s Master Class program in Barcelona were, from left, Jonathan Barker, Karina Jackson, Brian Kirby, Lluís Puig, Ulrich Mrowietz, and Catherine Smith.

The faculty for IPC’s Psoriasis Master Class in Mumbai, India, relax for a photo before starting the program’s second day. Seated, left to right, are Mumbai dermatologist Sushil Tahirani, IPC Board Member Lars Iversen, IPC Founding President Alan Menter, and IPC Councilor and program chair Murlidhar Rajagopalan.

IPC councilors who participated in the Chinese Psoriasis Conference in Hefei, China, were Anne Bowcock, Xuejun Zhang, and JT Elder.

Program sponsors: Novartis India and LEO Pharma
Biosimilars Working Group continues important work

IPC Biosimilars Working Group members reviewed country-specific regulatory guidelines for approval of biosimilars. In addition, the group examined biosimilar issues such as extrapolation, interchangeability, automatic substitution at the pharmacy level, and pharmacovigilance.

IPC convened a Hot Topics Roundtable discussion on biosimilars preceding the International Federation of Psoriasis Associations’ 5th World Psoriasis & Psoriatic Arthritis Conference in Stockholm, Sweden. IPC councilors, staff, invited speakers, and corporate partners attended the full-day program, which focused on interchangeability, physician education, and integration of biosimilars into clinical practice. Industry partners and regional thought leaders made presentations that highlighted a variety of perspectives on biosimilars in practice. Following the presentations, participants discussed current perspectives and data in view of updating IPC’s position on biosimilar issues.

Program chairs for this session were IPC councilors Arnon Cohen, Israel, and Jashin Wu, United States. Invited speakers were Gillian Woolett, senior vice president of the Washington, DC-based advisory services firm Avalere Health, and Dr. Jonathan Kay, professor of medicine and director of clinical research, rheumatology division, at the University of Massachusetts, Worcester. Additional presentations were made by IPC councilors Matías Maskin, Argentina, and Omid Zargari, Iran, and IPC Board Member Lluís Puig, Spain.

Project lead: Bruce Strober, MD, PhD, United States
Steering committee members: Andrew Blauvelt, MD, MBA, United States, Caítriona Ryan, MD, Ireland, and Joelle van der Walt, PhD, United States

Psoriasis severity classifications project has widespread participation

IPC’s network of key opinion leaders and stakeholders worked together to discuss challenges regarding the current definitions of psoriasis severity and how these definitions may limit treatment options for groups of patients with lower body surface area (BSA) and/or psoriasis on specific body sites. With this in mind, IPC embarked on a consensus-building exercise to classify all “categories” of psoriasis. Using the Delphi survey method, participants were able to suggest severity statements that refined or even replaced current definitions of mild, moderate, and severe psoriasis. The multi-stage voting exercise occurred over 4 months and was completed at the consensus meeting with a final round of voting on seven final statements during the December IPC Think Tank meeting in Miami, Florida.

It is envisioned that the consensus definitions will guide clinical decision-making to be practical, meaningful, and better aligned with the true severity of a patient’s disease; strengthen psoriasis treatment guidelines; and guide future clinical trials of drugs targeting various severities of psoriasis. Two manuscripts are currently in development.

Chair: Arnon Cohen, MD, MPH, PhD, and Jashin J. Wu, MD

IPC board members, councilors, staff, and corporate members gathered for a group photo after IPC’s Hot Topics Roundtable on biosimilars held as part of the International Federation of Psoriasis Associations (IFPA) World Psoriasis and Psoriatic Arthritis Conference in Stockholm, Sweden.

Following the conclusion of the IPC Think Tank, these Board Members & Councilors participated in the final round of voting to conclude the Psoriasis Severity Delphi project. IPC’s Fellows and staff were also in attendance to observe the voting.
Global Psoriasis Atlas makes great strides in 2018

The Global Psoriasis Atlas (GPA) is a joint project of the ILDS (International League of Dermatological Societies), IFPA (International Federation of Psoriasis Associations), and IPC (International Psoriasis Council). Its mission is to provide a common benchmark on the complete burden of psoriasis in countries and regions throughout the world.

The Global Psoriasis Atlas team made great strides in 2018 as they reached out to many parts of the world to understand the global burden of psoriasis and access to care. Work Stream One conducted an extensive systematic review of currently available literature, with the desired outcome of publications in suitable, high-impact scientific journals. This group also identified 53 unpublished epidemiological studies reporting on the incidence and prevalence of psoriasis in the general population. Additionally, they worked on a large-scale epidemiological study in Israel. Work Stream Two gathered and compiled the results of the sub-projects, global desk research and GPA online survey, both of which identified data sources. Parallel to this, the team completed the analysis of the field study on psoriasis care in 16 Latin American countries and began the process of evaluating the PsoHealth survey on psoriasis treatment. The GPA website, currently under development, will include collected data for all stakeholders to view.

IPC presents scientific symposia at IID

The International Investigative Dermatology (IID) held its 7th meeting in May 2018 in Orlando, Florida. IPC presented a symposium entitled “Psoriatic Disease Mechanistic Scenarios.” Co-chairs were IPC Councilors Johann Gudjonsson, MD, PhD, University of Michigan, United States, and Hervé Bachelez, MD, PhD, Hôpital Saint-Louis and Sorbonne Paris Cité Université, France. Presentations covered a wide spectrum of topics from the genetics of psoriasis variants to modeling psoriatic inflammation in mouse models. The IPC symposium closed with an array of exceptional poster presentations from a variety of international investigators.

Top 10 manuscripts in psoriasis research selected by IPC leadership


IPC spends its funds in three primary areas: Education, Patient Care, and Research.

- Education programs include the IPC Psoriasis Review newsletter, education symposia, and online professional education programs.
- Patient Care activities include our working groups, manuscript development, and advocacy activities.
- Research activities include special research projects and scientific symposia.
- Other programs include global outreach, including exhibiting and working with other organizations.
- Management and general expenses include funds spent on fundraising and organizational management.

*Numbers based on unaudited financial statements.

The International Psoriasis Council is proud to recognize the support of our corporate members and program sponsors from around the world. We thank these companies for joining with us to improve the lives of those living with psoriasis and its associated comorbidities.

Corporate members provide unrestricted funds to support IPC’s overall mission of improving psoriasis education, research, and treatment. Unrestricted funds allow IPC’s board of directors to implement the most important programs and research initiatives. In addition, IPC receives program grants to fund specific programs and initiatives.
Advancing Knowledge
Enhancing Care